Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 8/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 8/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18876439 | 0.76 | HSD17B1 (0.48) | HSD17B1HSD17B2KDM4ENPC1ALDH1A1 | |
| SCHEMBL714897 | 0.74 | HSD17B1 (0.52) | APPESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL19439597 | 0.74 | DAO (0.42) | DAO | |
| SCHEMBL4444739 | 0.73 | APP (0.70) | APPESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL27722991 | 0.73 | NPC1 (0.39) | APPESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL27702479 | 0.73 | HSD17B1 (0.47) | APPESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL145588 | 0.72 | DAO (0.37) | APPESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL27867619 | 0.71 | PRKCI (0.50) | APPESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL7733123 | 0.70 | PGR (0.43) | APPESR1ESR2 | |
| SCHEMBL1514398 | 0.68 | CYP2E1 (0.51) | APPKDM4EALDH1A1HPGDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190216804-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216804-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | MGLL, LIPA, PNLIP | APP 3219/4885ESR1 4433/4885ESR2 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.